Can nitroglycerin intravenous infusion cause respiratory shunting?

Yes, nitroglycerin infusion can cause respiratory shunting and worsen hypoxemia

Intravenous nitroglycerin may aggravate hypoxemia by increasing ventilation-perfusion (V/Q) mismatch and intrapulmonary shunting, particularly in patients with underlying lung pathology. This is a recognized adverse effect documented in major cardiology guidelines and should be monitored during administration.

Mechanism and Clinical Evidence

The mechanism behind nitroglycerin-induced respiratory shunting involves:

• Inhibition of hypoxic pulmonary vasoconstriction (HPV): Nitroglycerin's vasodilatory effects override the normal compensatory mechanism where poorly ventilated lung regions constrict their blood vessels to redirect blood flow to better-ventilated areas 1

• Increased perfusion to low V/Q regions: By dilating pulmonary vessels indiscriminately, nitroglycerin increases blood flow through poorly ventilated lung segments, worsening the mismatch between ventilation and perfusion 2, 3, 4

Research studies demonstrate this effect clearly:

• In post-cardiac surgery patients ventilated with 100% oxygen, nitroglycerin infusion significantly increased shunt from 9.3% to 16.5% of cardiac output, with PaO2 dropping from 50.5 to 32.7 kPa 2
• In patients with normal lung function under general anesthesia, nitroglycerin increased shunt from 5.13% to 6.19% 3
• In oleic acid-induced pulmonary edema models, nitroglycerin decreased PaO2 from 64 to 55 torr, primarily due to increased venous admixture 4

Clinical Implications and Monitoring

The ACC/AHA guidelines explicitly warn that "nitroglycerin may aggravate hypoxemia by increasing ventilation-perfusion mismatch" 1. This is particularly concerning in:

• Patients with acute heart failure and underlying lung disease
• Those with pulmonary edema where V/Q matching is already compromised
• Patients receiving high FiO2 (the shunting effect is more pronounced with oxygen breathing)

Important caveats:

• The magnitude of shunting is generally greater with sodium nitroprusside than nitroglycerin 3
• In patients with chronic obstructive pulmonary disease (COPD) and established pulmonary hypertension, the effect may be less pronounced due to fixed vascular changes 3, 5
• The clinical significance depends on baseline lung function—patients with normal lungs typically tolerate the modest increase in shunt without severe hypoxemia

Practical Management Approach

When using IV nitroglycerin:

1. Monitor oxygen saturation continuously, especially during dose titration

2. Ensure adequate oxygenation before and during infusion—maintain SpO2 ≥90% 6

3. Start at low doses (10-20 mcg/min) and titrate slowly 7, 8

4. Be particularly cautious in patients with:

   • Pre-existing hypoxemia
   • Significant pulmonary disease
   • Acute respiratory distress

5. If significant hypoxemia develops:

   • Increase supplemental oxygen
   • Consider reducing nitroglycerin dose
   • Evaluate for alternative vasodilators if blood pressure control is still needed

The ESC guidelines note that while vasodilators relieve pulmonary congestion without compromising stroke volume in acute heart failure, clinicians must balance hemodynamic benefits against potential worsening of gas exchange 7, 8. The effect on oxygenation is typically modest and manageable with supplemental oxygen, but awareness and monitoring are essential to prevent clinically significant hypoxemia.